scPharmaceuticals Overview
Valuation check: SCPH's ROE is 430.27%, above the Healthcare sector average of 20.77%.
Get informed when a big investor buys or sells
+ Follow430.27%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
scPharmaceuticals (SCPH) currently reports a ROE of 430.27%. That is above the Healthcare sector average of 20.77%. Use the charts on this page to explore scPharmaceuticals's ROE history and peer comparisons.
scPharmaceuticals's ROE of 430.27% is higher than the Healthcare sector average of 20.77%. That is roughly 1972.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but scPharmaceuticals's current 430.27% should be judged against Healthcare norms (sector average: 20.77%) and against SCPH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 430.27%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for scPharmaceuticals, and consider following SCPH for alerts when major investors trade the stock.
scPharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 430.27% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SCPH with unrelated industries.
